MX2017014835A - Cristal de sal de derivado de 3-azabiciclo[3.1.0]hexano novedoso y usos medicionales del mismo. - Google Patents

Cristal de sal de derivado de 3-azabiciclo[3.1.0]hexano novedoso y usos medicionales del mismo.

Info

Publication number
MX2017014835A
MX2017014835A MX2017014835A MX2017014835A MX2017014835A MX 2017014835 A MX2017014835 A MX 2017014835A MX 2017014835 A MX2017014835 A MX 2017014835A MX 2017014835 A MX2017014835 A MX 2017014835A MX 2017014835 A MX2017014835 A MX 2017014835A
Authority
MX
Mexico
Prior art keywords
crystal
salt
azabicyclo
novel
group
Prior art date
Application number
MX2017014835A
Other languages
English (en)
Inventor
Kuno Yuka
Iwamura Ryo
Tsuzaki Yasunori
Setoguchi Hiroyuki
Akaza Hiroto
Yamamoto Yasuhito
Takama Akira
Original Assignee
Sanwa Kagaku Kenkyusho Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanwa Kagaku Kenkyusho Co filed Critical Sanwa Kagaku Kenkyusho Co
Publication of MX2017014835A publication Critical patent/MX2017014835A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/06—Oxalic acid
    • C07C55/07—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

En la presente se describe un cristal que comprende un compuesto, que tiene acción antagonista del receptor µ-opioide, pocos efectos secundarios, y alta seguridad, y que tiene alta pureza y excelentes propiedades físicas (estabilidad, solubilidad, etc.), y un método para producir el cristal. El cristal es un cristal de una sal que comprende: un compuesto representado por una fórmula (I) (ver Fórmula) donde R2 es un átomo de hidrógeno o un átomo de halógeno, y R1 es un grupo seleccionado del grupo que consiste en (ver Fórmula) y un ácido seleccionado del grupo que consiste en ácido clorhídrico, ácido bromhídrico, y ácido oxálico, o un hidrato de los mismos.
MX2017014835A 2015-05-20 2016-05-19 Cristal de sal de derivado de 3-azabiciclo[3.1.0]hexano novedoso y usos medicionales del mismo. MX2017014835A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015103161 2015-05-20
PCT/JP2016/064942 WO2016186184A1 (ja) 2015-05-20 2016-05-19 新規３－アザビシクロ［３．１．０］ヘキサン誘導体の塩の結晶及びその医薬用途

Publications (1)

Publication Number Publication Date
MX2017014835A true MX2017014835A (es) 2018-02-19

Family

ID=57320492

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014835A MX2017014835A (es) 2015-05-20 2016-05-19 Cristal de sal de derivado de 3-azabiciclo[3.1.0]hexano novedoso y usos medicionales del mismo.

Country Status (11)

Country Link
US (1) US10392345B2 (es)
EP (1) EP3299357A4 (es)
JP (1) JP6087035B1 (es)
KR (1) KR20180004734A (es)
CN (2) CN113307760A (es)
AU (1) AU2016265801B2 (es)
CA (1) CA2985327A1 (es)
HK (1) HK1246778A1 (es)
MX (1) MX2017014835A (es)
RU (1) RU2017144548A (es)
WO (1) WO2016186184A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018229062A1 (en) * 2017-03-02 2019-09-26 Ube Industries, Ltd. Therapeutic agent for alcohol use disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI244481B (en) * 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
GB0015562D0 (en) 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
US20020025948A1 (en) 2000-06-23 2002-02-28 Banks Bernard Joseph 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
HUP0401884A2 (hu) * 2001-10-22 2005-01-28 Pfizer Products Inc. Opioid receptor antagonista hatású 3-azabiciklo[3.1.0]hexán-származékok és ezeket tartalmazó gyógyszerkészítmények
US20050043327A1 (en) 2003-08-21 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US20050043345A1 (en) 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US7153976B2 (en) 2003-10-06 2006-12-26 Pfizer Inc. Purification process for an azabicyclo[3.1.0]hexane compound
EP1675829A1 (en) * 2003-10-16 2006-07-05 Pfizer Products Inc. Preparation of 3-azabicyclo [3.1.0] hexane derivatives
WO2008075162A2 (en) 2006-12-15 2008-06-26 Pfizer Limited Selective mu opioid receptor antagonists for the treatment of female sexual dysfunction
ES2774349T3 (es) 2013-11-20 2020-07-20 Sanwa Kagaku Kenkyusho Co Derivado de 3-azabiciclo[3.1.0]hexano y su uso para fines médicos

Also Published As

Publication number Publication date
JP6087035B1 (ja) 2017-03-01
RU2017144548A (ru) 2019-06-20
WO2016186184A1 (ja) 2016-11-24
CN107428687B (zh) 2021-06-11
AU2016265801A1 (en) 2017-11-30
CN113307760A (zh) 2021-08-27
RU2017144548A3 (es) 2019-10-17
KR20180004734A (ko) 2018-01-12
CA2985327A1 (en) 2016-11-24
CN107428687A (zh) 2017-12-01
US10392345B2 (en) 2019-08-27
EP3299357A4 (en) 2018-11-14
JPWO2016186184A1 (ja) 2017-06-15
HK1246778A1 (zh) 2018-09-14
US20180148409A1 (en) 2018-05-31
AU2016265801B2 (en) 2020-10-08
EP3299357A1 (en) 2018-03-28

Similar Documents

Publication Publication Date Title
MX2018011831A (es) Antagonistas solubles de receptor de c5aa(c5ar).
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
PH12019500480A1 (en) Pyridine compound
MX2016017030A (es) Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos.
MY196572A (en) Amino-Methyl Piperidine Derivative as Kinase Inhibitor
PH12015502524B1 (en) New somatostatin receptor subtype 4 (sstr4) agonists
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
TN2020000125A1 (en) Amino-fluoropiperidine derivative as kinase inhibitor
IN2014MN02106A (es)
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MY197698A (en) Oxysterols and methods of use thereof
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
NZ711424A (en) Pyridine derivatives as soft rock inhibitors
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
MX2013011589A (es) Metodos y composiciones para tratar enfermedad de parkinson.
PH12018501644A1 (en) Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
MX2016004963A (es) Sal y formas cristalinas de inhibidores de quinasa tipo polo-4.
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
MX2016008536A (es) Derivados de fluoro-naftilo.
MX2017008382A (es) Formas cristalinas de apomorfina y sus usos.
MX341341B (es) Derivados de benzamida y su uso como inhibidores de proteina de choque termico 90 kda (hsp90).
MX369345B (es) Procesos para la preparacion de analogos de oxitocina.
MX2017014835A (es) Cristal de sal de derivado de 3-azabiciclo[3.1.0]hexano novedoso y usos medicionales del mismo.